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Identity 
Other names: Hepatocholangiocellular carcinoma 
Note: Defined as an intrahepatic tumor nodule that 
contains both hepatocellular carcinoma and 
cholangiocarcinoma. 
Classification 
Note: Tumor staging is separated by TNM 
classification. 
TNM classifications for hepatocellular and 
cholangiocarcinomas of the liver. 
Clinics and pathology 
Disease  
Combined hepatocellular and cholangiocarcinoma is a 
more aggressive malignancy with a poorer prognosis 
than ordinary hepatocellular carcinoma (HCC). 
Etiology 
The reported frequency of combined hepatocellular and 
cholangiocarcinoma (combined tumors) varies widely; 
1.0-6.5% among patients with primary liver cancer. 
Statistical data indicate that combined tumors occur 
predominantly in men (reported ratio is ranged from 
14:1 to 2:1). The mean age of onset is in the sixth 
decade. In Asian cases, a high incidence of hepatitis B 
or C virus infection and frequent association of chronic 
liver disease/cirrhosis have been reported. Conversely, 
in Western countries, these features are less common. 
Combined tumors exhibit an invasive character with  
frequent venous permeation and tumor microsatellite 
formation, features that are seen more frequently than 
in ordinary HCC. 
Epidemiology 
A rare subtype of primary liver cancer. 
Clinics 
The typical clinical symptom is abdominal pain. 
Complaints of fatigue and weakness are mostly 
attributable to compromised liver function. Jaundice is 
found in a much lower percentage of patients than of 
those with intrahepatic cholangiocarcinoma (CC). 
Chills and fever appear rarely. 
In combined tumors, HCC and CC areas rarely can be 
identified using imaging techniques such as 
ultrasonography, helical CT, and dynamic MRI. In 
many cases, even in tumor biopsy samples, the two 
components are not included or discriminated. 
Generally, final diagnosis is entrusted to pathological 
findings of surgically resected or autopsy samples. 
Pathology 
The histopathological classification reported by 
Goodman et al. is popular:  
- type I, in which HCC and CC occur coincidentally 
and no transitional forms are observed; 
- type II, in which there are areas of apparent transition 
between HCC and CC; 
- type III, in which tumor cells resemble the 
fibrolamellar subtype of HCC but contain mucin-
producing glands. 
Other classifications, reported by Allen and Lisa, and 
by Kojiro et al., are known. 
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 (A and B) Gross feature and schematic illustration of combined hepatocellular and cholangiocarcinoma. HCC: hepatocellular carcinoma, 
CC: cholangiocarcinoma. (C-E) Border zone between HCC and CC. Moderately differentiated HCC (right) with vague grandular 
component (left). The grandular tumor cells were positive for CK19 and HCC component was positive for Hep par-1. 
Treatment 
Surgical resection, chemotherapy, radiofrequency 
ablation, microwave coagulation, ethanol injection, 
transarterial embolization. 
Evolution 
Intrahepatic recurrence is common. Combined tumors 
have been reported to be more aggressive than HCC, 
with widespread metastasis and regional lymph node 
involvement. 
Prognosis 
The prognosis of combined tumors is poorer than that 
of HCC because of relatively frequent lymph node 
metastasis and vascular invasion. Survival rates of 
patients with combined tumors are generally poorer 
than those of patients with HCC. 
Cytogenetics 
Note: Loss of heterozygosity (LOH) at 4q, 8p, 13q, 
16q, and 17p is seen frequently in combined 
hepatocellular and cholangiocarcinoma similar to in 
HCC. LOH at 3p and 14q are reported to be specific in 
CC and combined hepatocellular-cholangiocarcinoma 
in contrast to HCC. 
 







Proto-oncogene. GTP-GDP binding protein with 
GTPase activity. The K-ras proto-oncogene is thought 
to exert control over some of the mechanisms of cell 
growth and differentiation. This gene is converted to an 
active oncogene by point mutations concentrated 
significantly in codons 12, 13, and 61. 
Mutations of the K-ras gene have been reported to be 
common (67-75%) in intrahepatic CC. Conversely, the 
mutations rarely have been found in HCC. K-ras 
mutations in combined hepatocellular and 
cholangiocarcinoma have been analyzed in Japanese 
cases and it has been reported that the mutations were 
found rarely, as in the case for HCC. This observation 
may reflect the background of Japanese patients; 
specifically, chronic hepatitis C infection and evidence  
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Tumor suppressor. Wild-type p53 plays an important 
role in the regulation of the cell cycle process, cell 
growth, and apoptosis in the event of DNA damage. 
The aberrant proteins from the mutated genes disrupt 
critical growth-regulating mechanisms and may play a 
crucial role in the carcinogenesis. The reported 
incidence of p53 mutation is 11-37% in intrahepatic CC 
and 10-29% in combined hepatocellular and 
cholangiocarcinoma. In HCC, the frequency of p53 
mutations varies among different geographic areas. p53 
abnormalities appear not to be correlated with tumoral 
differentiation. 
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